Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$428560.0.

  • Regenerative Medical Technology's Free Cash Flow fell 29539.15% to -$428560.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$640151.0, marking a year-over-year decrease of 841944.37%. This contributed to the annual value of $635280.0 for FY2024, which is 17893.69% up from last year.
  • Regenerative Medical Technology's Free Cash Flow amounted to -$428560.0 in Q3 2025, which was down 29539.15% from -$598093.0 recorded in Q2 2025.
  • Over the past 5 years, Regenerative Medical Technology's Free Cash Flow peaked at $329393.0 during Q4 2024, and registered a low of -$8.7 million during Q4 2021.
  • Its 5-year average for Free Cash Flow is -$645861.1, with a median of -$187420.0 in 2022.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 892508.69% in 2021, then soared by 368681.15% in 2024.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Free Cash Flow stood at -$8.7 million in 2021, then skyrocketed by 97.86% to -$187420.0 in 2022, then crashed by 67.22% to -$313401.0 in 2023, then surged by 205.1% to $329393.0 in 2024, then tumbled by 230.11% to -$428560.0 in 2025.
  • Its Free Cash Flow was -$428560.0 in Q3 2025, compared to -$598093.0 in Q2 2025 and $57109.0 in Q1 2025.